Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.

[1]  Chen Lam Hiew.  Endocrine Approaches in the Therapy of Prostate Carcinoma , 2011 .

[2]  A. Bono,et al.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. , 2009, European urology.

[3]  D. Jocham,et al.  Degarelix for prostate cancer , 2009, Expert opinion on investigational drugs.

[4]  J. Leitner,et al.  The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references. , 2008, International journal of clinical pharmacology and therapeutics.

[5]  Matthew R. Smith.  Androgen deprivation therapy for prostate cancer: new concepts and concerns , 2007, Current opinion in endocrinology, diabetes, and obesity.

[6]  F. Bladou,et al.  LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion* , 2007, Current medical research and opinion.

[7]  H. Lepor,et al.  Androgen deprivation therapy in the treatment of advanced prostate cancer. , 2007, Reviews in urology.

[8]  W. Dahut,et al.  Androgen deprivation therapy for prostate cancer. , 2005, JAMA.

[9]  P. Walsh.  6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial , 2005 .

[10]  R. Schall,et al.  Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer , 2003, BJU international.

[11]  M. Motta,et al.  Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. , 2003, Endocrine-related cancer.

[12]  O. Sartor.  Eligard: leuprolide acetate in a novel sustained-release delivery system. , 2003, Urology.

[13]  D. Mcleod,et al.  Hormonal therapy: historical perspective to future directions. , 2003, Urology.

[14]  E. Loizides,et al.  A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. , 2002, Clinical therapeutics.

[15]  R. Sharifi,et al.  Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. , 2002, The Journal of urology.

[16]  R. Harkaway,et al.  A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. , 2002, The Journal of urology.

[17]  R. Persad.  LEUPRORELIN ACETATE IN PROSTATE CANCER: A EUROPEAN UPDATE , 2002, International journal of clinical practice.

[18]  K. Pienta,et al.  The Current State of Hormonal Therapy for Prostate Cancer , 2002, CA: a cancer journal for clinicians.

[19]  Thomas C. Melvin,et al.  European Patent Office , 2002 .

[20]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[21]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[22]  D. Gleason,et al.  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. , 2001, Urology.

[23]  M. Gleave,et al.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. , 2001, The Journal of urology.

[24]  G. Bubley,et al.  Is the flare phenomenon clinically significant? , 2001, Urology.

[25]  M. Gleave,et al.  Is the flare phenomenon clinically significant? Commentary , 2001 .

[26]  I. Thompson.  Flare Associated with LHRH-Agonist Therapy. , 2001, Reviews in urology.

[27]  D. Jocham.  Leuprorelin Three-Month Depot in the Treatment of Advanced and Metastatic Prostate Cancer: Long-Term Follow-Up Results , 1998, Urologia Internationalis.

[28]  R. Bruskewitz,et al.  Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. , 1996, Clinical therapeutics.

[29]  G. Lübben,et al.  Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group. , 1996, Urologia internationalis.

[30]  P. Schellhammer,et al.  Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. , 1995, Urology.

[31]  R. N. Brogden,et al.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. , 1994, Drugs.

[32]  E. Sorkin,et al.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. , 1991, Drugs & aging.

[33]  M. Soloway,et al.  Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. , 1990, The Journal of urology.

[34]  L. Sennello,et al.  Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. , 1986, Journal of pharmaceutical sciences.

[35]  J. Smith,et al.  Endocrine and clinical effects of leuprolide in prostatic cancer , 1984, Clinical pharmacology and therapeutics.

[36]  J. Wass,et al.  Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. , 1983, British medical journal.

[37]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[38]  C. Bergquist,et al.  Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. , 1979, Acta endocrinologica.

[39]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.